ES2339846T3 - Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob. - Google Patents

Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob. Download PDF

Info

Publication number
ES2339846T3
ES2339846T3 ES02011474T ES02011474T ES2339846T3 ES 2339846 T3 ES2339846 T3 ES 2339846T3 ES 02011474 T ES02011474 T ES 02011474T ES 02011474 T ES02011474 T ES 02011474T ES 2339846 T3 ES2339846 T3 ES 2339846T3
Authority
ES
Spain
Prior art keywords
protein
amino acids
amino acid
increase
mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02011474T
Other languages
English (en)
Spanish (es)
Inventor
Mary Ann Pelleymounter
Christopher Francis Toombs
Michael Benjamin Mann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2339846T3 publication Critical patent/ES2339846T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES02011474T 1995-11-22 1996-11-04 Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob. Expired - Lifetime ES2339846T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22
US561732 1995-11-22

Publications (1)

Publication Number Publication Date
ES2339846T3 true ES2339846T3 (es) 2010-05-26

Family

ID=24243198

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02011474T Expired - Lifetime ES2339846T3 (es) 1995-11-22 1996-11-04 Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob.
ES96938773T Expired - Lifetime ES2217327T3 (es) 1995-11-22 1996-11-04 Proteina ob para aumentar la masa de tejido magro.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96938773T Expired - Lifetime ES2217327T3 (es) 1995-11-22 1996-11-04 Proteina ob para aumentar la masa de tejido magro.

Country Status (15)

Country Link
EP (3) EP1285664B1 (enExample)
JP (2) JP4173914B2 (enExample)
AT (2) ATE455554T1 (enExample)
AU (3) AU7607496A (enExample)
CA (2) CA2358862A1 (enExample)
DE (2) DE69638119D1 (enExample)
DK (1) DK0866720T3 (enExample)
ES (2) ES2339846T3 (enExample)
IL (2) IL124442A0 (enExample)
MX (1) MX9803992A (enExample)
NZ (3) NZ527007A (enExample)
PT (1) PT866720E (enExample)
SI (1) SI0866720T1 (enExample)
WO (1) WO1997018833A1 (enExample)
ZA (1) ZA969605B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
DE69638119D1 (de) * 1995-11-22 2010-03-11 Amgen Inc Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
WO1997026916A1 (en) * 1996-01-25 1997-07-31 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
AU2810497A (en) * 1996-04-19 1997-11-12 University Of Washington Methods for inducing bone formation
JP2001507228A (ja) * 1996-12-20 2001-06-05 イーライ・リリー・アンド・カンパニー 抗肥満タンパク質
AU5606098A (en) * 1996-12-20 1998-07-17 Amgen, Inc. Ob fusion protein compositions and methods
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
AU3863699A (en) * 1998-04-20 1999-11-08 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU1134000A (en) * 1998-10-27 2000-05-15 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
WO2000047741A1 (en) * 1999-02-12 2000-08-17 Amgen Inc. Glycosylated leptin compositions and related methods
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
EP1765411B2 (en) * 2004-06-30 2017-10-11 Nektar Therapeutics Polymer-factor ix moiety conjugates
CN101094689B (zh) 2004-11-01 2013-06-12 安米林药品有限责任公司 治疗肥胖以及肥胖相关疾病和病症的方法
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
CN103547590B (zh) 2010-09-28 2017-11-28 埃格里昂制药股份有限公司 高度可溶性瘦蛋白
PL2900230T3 (pl) 2012-09-27 2019-02-28 The Children's Medical Center Corporation Związki do leczenia otyłości i sposoby ich zastosowania
ES2709976T3 (es) 2013-11-26 2019-04-22 Childrens Medical Ct Corp Compuestos para el tratamiento de la obesidad y procedimientos de uso de los mismos
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
SI3509624T1 (sl) 2016-09-12 2023-12-29 Amryt Pharmaceuticals, Inc., Postopki detektiranja nevtralizirajočih protiteles proti leptinu

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
AU7535394A (en) * 1993-08-13 1995-03-14 Putzmeister-Werk Maschinenfabrik Gmbh Process and device for treating the surface of large objects
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
DE69638119D1 (de) * 1995-11-22 2010-03-11 Amgen Inc Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
NZ326592A (en) * 1995-12-27 2001-05-25 Genentech Inc Long half life derivatives of the OB protein and use in the treatment of OB gene related disorders
AU5606098A (en) * 1996-12-20 1998-07-17 Amgen, Inc. Ob fusion protein compositions and methods
CN1202862C (zh) * 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法

Also Published As

Publication number Publication date
EP0866720B1 (en) 2004-02-11
DE69631544T2 (de) 2004-12-23
ATE259243T1 (de) 2004-02-15
ES2217327T3 (es) 2004-11-01
JP4227325B2 (ja) 2009-02-18
ZA969605B (en) 1997-06-02
NZ527007A (en) 2005-01-28
JP4173914B2 (ja) 2008-10-29
IL127926A (en) 2006-08-20
AU763755B2 (en) 2003-07-31
DK0866720T3 (da) 2004-06-14
DE69638119D1 (de) 2010-03-11
IL127926A0 (en) 1999-11-30
IL124442A0 (en) 1998-12-06
CA2236163A1 (en) 1997-05-29
ATE455554T1 (de) 2010-02-15
EP0956862A1 (en) 1999-11-17
SI0866720T1 (en) 2004-10-31
NZ511617A (en) 2003-08-29
AU7607496A (en) 1997-06-11
NZ512083A (en) 2003-02-28
AU4265200A (en) 2000-09-21
AU4265300A (en) 2000-09-07
PT866720E (pt) 2004-06-30
DE69631544D1 (de) 2004-03-18
EP0866720A1 (en) 1998-09-30
EP1285664A3 (en) 2003-07-30
EP1285664A2 (en) 2003-02-26
MX9803992A (es) 1998-09-30
AU763769B2 (en) 2003-07-31
WO1997018833A1 (en) 1997-05-29
JP2000500492A (ja) 2000-01-18
JP2002206000A (ja) 2002-07-23
EP1285664B1 (en) 2010-01-20
CA2358862A1 (en) 1997-05-29

Similar Documents

Publication Publication Date Title
ES2339846T3 (es) Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob.
JP4173913B2 (ja) Ｏｂタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法
Gualandi-Signorini et al. Insulin formulations-a review
US7718400B2 (en) Methods of increasing lean tissue mass using OB protein compositions
CA2230968A1 (en) Method of treating insulin resistance
US7816321B2 (en) Thymosin β4 derivatives and use thereof
EP0515434B1 (en) Method for treating intestinal diseases
KR20010006392A (ko) 안정한 활성 인체 ｏｂ 단백질 및 항체 ｆｃ 사슬 복합체를 함유하는 조성물 및 방법
JP3034032B2 (ja) 腸疾患用薬剤
TW492869B (en) Use of GIP-1 or analogs to abolish catabolic changes after surgery
AU2006201747B2 (en) Methods of Increasing Lean Tissue Mass Using OB Protein Compositions
AU2004200516B2 (en) Methods of Increasing Lean Tissue Mass Using OB Protein Compositions
AU2003201360B2 (en) Methods of Reducing or Maintaining Reduced Levels of Blood Lipids Using OB Protein Compositions
HK1022438A (en) Methods of increasing lean tissue mass using ob protein compositions
AU7226291A (en) Method for treating intestinal diseases